Last reviewed · How we verify
Monovalent subvirion H5N1 influenza vaccine
Monovalent subvirion H5N1 influenza vaccine is a Biologic drug developed by Sanofi. It is currently in Phase 1 development.
At a glance
| Generic name | Monovalent subvirion H5N1 influenza vaccine |
|---|---|
| Sponsor | Sanofi |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses (PHASE2)
- H5N1 With or Without Topical Aldara in Healthy Adults (PHASE1)
- H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo... (PHASE1)
- H5N1 Vaccination With and Without AS03: Systems Biology Analysis (PHASE1)
- Development of Immune Globulin Treatment for Avian Flu (PHASE2)
- H5N1 (Clade 2) Vaccination of Adults and Elderly (PHASE1, PHASE2)
- Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines (PHASE1)
- H5 Adult - Chiron Study of Bird Flu Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monovalent subvirion H5N1 influenza vaccine CI brief — competitive landscape report
- Monovalent subvirion H5N1 influenza vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Monovalent subvirion H5N1 influenza vaccine
What is Monovalent subvirion H5N1 influenza vaccine?
Monovalent subvirion H5N1 influenza vaccine is a Biologic drug developed by Sanofi.
Who makes Monovalent subvirion H5N1 influenza vaccine?
Monovalent subvirion H5N1 influenza vaccine is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
What development phase is Monovalent subvirion H5N1 influenza vaccine in?
Monovalent subvirion H5N1 influenza vaccine is in Phase 1.